Cadrenal Therapeutics Inc(CVKD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:25 AM ET (Korea 9/29 18:25)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.9 | Insider Own | 9.66% | Shs Outstand | 3.6M | Perf Week | 2.75% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 22.17% | Insider Trans | -22.06% | Shs Float | 3.2M | Perf Month | -28.43% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.91 | Inst Own | 10.09% | Short Float | 3.69% | Perf Quarter | -62.91% |
| Income | -0.01B | P/S | - | EPS this Y | 41.82% | Inst Trans | 18.83% | Short Ratio | 0.27 | Perf Half Y | -77.56% |
| Sales | 0.00B | P/B | 0.85 | EPS next 5Y | 34.69% | ROA | -199.59% | Short Interest | 0.12M | Perf YTD | -83.48% |
| Book/sh | 1.32 | P/C | 1.67 | EPS past 3/5Y | 8.46% - | ROE | -275.16% | 52W High | -92.35% ($14.64) | Perf Year | -92.02% |
| Cash/sh | 0.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -282.13% | 52W Low | 12% ($1.00) | Perf 3Y | -88.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 44.8% | Gross Margin | - | Volatility(W/M) | 13.49% 12.43% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.67 | EPS Q/Q | 38.99% | Profit Margin | - | RSI (14) | 37.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.67 | Sales Q/Q | - | SMA20 | -7.17% ($1.21) | Beta | 1.88 | Target Price | $14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -29.99% ($1.6) | Rel Volume | 0.18 | Prev Close | $1.15 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 19.72% - | SMA200 | -76.71% ($4.81) | Avg Volume(3M) | 0.43M | Price | $1.12 |
| IPO | 2023/1/20 | Option/Short | No/Yes | Trades | 278 | Volume | 75,647 | Change | -2.61% |
🩸 This is a small-cap U.S. biotech listed on NASDAQ that develops treatments for rare cardiovascular diseases, centered on Tecarfarin, an anticoagulant designed to deliver a more stable blood-thinning effect than the existing anticoagulant warfarin. The company is an ultra-small-cap listed firm expanding its clinical-stage pipeline, targeting specialized patient groups, including those with left ventricular assist devices (LVADs) and end-stage kidney disease (ESKD) patients with atrial fibrillation.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual That is 18% of its average volume.
CVKD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +41.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -88.9%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #558 of 592 in the industry
Based on market cap of $4M.
HCWB#557 HCW Biologics Inc $4M PER - CVKD#558 Cadrenal Therapeutics Inc $4M PER - 
CLDI#559 Calidi Biotherapeutics Inc $4M PER - 
ELAB#560 PMGC Holdings Inc $4M PER - 
MBIO#561 Mustang Bio Inc $4M PER - 
FAQ
What kind of company is CVKD?
CVKD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CVKD?
The market cap of CVKD is approximately $4M, ranking 5,734 within its sector.
What is the 52-week high and low for CVKD?
CVKD has recorded a 52-week high of $14.64 and a low of $1.00.
